Empirical Wealth Management
VRTX icon

Empirical Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Empirical Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$281K Buy
537
+123
+30% +$63K ﹤0.01% 985
2026
Q2 		$206K Sell
414
-245
-37% -$109K ﹤0.01% 1008
2026
Q1 		$294K Sell
659
-1,172
-64% -$546K 0.01% 797
2025
Q4 		$830K Buy
1,831
+156
+9% +$67.2K 0.01% 371
2025
Q3 		$656K Sell
1,675
-377
-18% -$158K 0.01% 402
2025
Q2 		$914K Buy
2,052
+215
+12% +$99.1K 0.02% 322
2025
Q1 		$891K Buy
1,837
+1,146
+166% +$534K 0.02% 312
2024
Q4 		$278K Sell
691
-153
-18% -$70.9K 0.01% 518
2024
Q3 		$393K Sell
844
-3
-0.4% -$1.44K 0.01% 418
2024
Q2 		$397K Sell
847
-404
-32% -$175K 0.01% 400
2024
Q1 		$523K Buy
1,251
+203
+19% +$85.8K 0.02% 334
2023
Q4 		$426K Buy
1,048
+68
+7% +$25.1K 0.01% 344
2023
Q3 		$341K Sell
980
-21
-2% -$7.34K 0.01% 351
2023
Q2 		$352K Sell
1,001
-345
-26% -$116K 0.01% 352
2023
Q1 		$424K Hold
1,346
– – 0.02% 348
2022
Q4 		$389K Sell
1,346
-39
-3% -$11.9K 0.02% 348
2022
Q3 		$401K Sell
1,385
-393
-22% -$113K 0.02% 332
2022
Q2 		$501K Sell
1,778
-307
-15% -$82.2K 0.03% 294
2022
Q1 		$544K Sell
2,085
-1,815
-47% -$431K 0.03% 316
2021
Q4 		$856K Sell
3,900
-2,072
-35% -$403K 0.04% 243
2021
Q3 		$1.08M Buy
5,972
+2,031
+52% +$397K 0.06% 180
2021
Q2 		$795K Buy
3,941
+1,529
+63% +$320K 0.05% 219
2021
Q1 		$518K Buy
+2,412
New +$530K 0.04% 243

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Empirical Wealth Management's VRTX Position: Q3 2026 in Review

Empirical Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 30% in Q3 2026, buying an estimated $63K and bringing the position to 537 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #985.

Empirical Wealth Management first reported a position in VRTX in Q1 2021 and has held it in 23 quarters since. The position peaked at $1.08M in Q3 2021. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Empirical Wealth Management held 537 shares of Vertex Pharmaceuticals worth $281K as of Q3 2026.
  • Empirical Wealth Management bought 123 Vertex Pharmaceuticals shares in Q3 2026, an estimated $63K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Empirical Wealth Management's portfolio in Q3 2026, its #985 holding.
  • Empirical Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 23 quarters since.
  • Empirical Wealth Management's Vertex Pharmaceuticals position peaked at $1.08M in Q3 2021.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Empirical Wealth Management's 13F filing for Q3 2026, filed 27 Oct 2026.